CDKL5 and craniodiaphyseal dysplasia: Here, we confirmed that the low CDKL5 levels re-expressed in the brains of AAV vector-treated Cdkl5 − /Y mice are sufficient to ameliorate CDD phenotypes if supported by an increased biodistribution due to the properties of the Igk-TATk fusion protein.